Common problems in the management of hypertriglyceridemia

CMAJ. Canadian Medical Association Journal

Volumn 167, Issue 11, 2002, Pages 1261-1266

  Fung, Michelle A ^a   Frohlich, Jiri J ^a  

^a ST PAUL S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BILE ACID; COD LIVER OIL; CYCLOSPORIN; ESTROGEN; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; ISOTRETINOIN; NICOTINIC ACID; OMEGA 3 FATTY ACID; PROTEINASE INHIBITOR; STATIN; VITAMIN B GROUP; WARFARIN;

ADULT; ANAMNESIS; ARTICLE; BODY HEIGHT; BODY WEIGHT; CARDIOVASCULAR RISK; CASE REPORT; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; DIAGNOSTIC PROCEDURE; DRUG INDUCED DISEASE; DYSLIPIDEMIA; FAMILY HISTORY; FLUSHING; GASTRITIS; HUMAN; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; HYPERURICEMIA; LIPID BLOOD LEVEL; LIVER TOXICITY; MALE; MYOSITIS; PHYSICAL EXAMINATION; PRURITUS; SERUM; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0036436496     PISSN: 08203946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Lipids. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The Metabolic and Molecular Basis of Inherited Disease. 8th Ed. New York: McGraw-Hill; 2001. p. 2703-988.
2. Stampfer MJ, Krauss RM, Ma J, Blanche PJ, Holl LG, Sacks FM, et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 1996;276:882.
3. Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 1998;81:7B.
4. Dobiasova M, Frohlich J. The plasma parameter log (TG/HDL-C) as an atherogenic index: Correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FERHDL). Clin Biochem 2001:34:583-8.
5. Zhao XQ, Morse J, Chait A, Fisher L, Dowdy A, Albers J, et al. Simvistatin plus niacin protect against atherosclerosis progression and clinical events in coronary artery disease patients with metabolic syndrome [abstract 1130-73]. J Am Coll Cardiol 2002;39(5, Suppl A).
6. Despres JP, Lemieux I, Prud'homme D. Treatment of obesity: Need to focus on high risk abdominally obese patients. BMJ 2001;332:716-20.
7. Sniderman AD, Bergeron J, Frohlich J. Apolipoprotein B versus lipoprotein lipids: Vital lessons from the AFCAPS/TexCAPS trial. CMAJ 2001:164(1):44-7.
8. Fodor J, Frohlich J, Genest J, McPherson R, for the Working Group on Hypercholesterolemia and Other Dyslipidemias. Recommendations for the management and treatment of dyslipidemia. CMAJ 2000;162(10):1441-7.
9. Cantin B, Gagnon F, Moorjani S, Despres JP, Lamarche B, Lupien PJ, Dagenais GR. Is lipoprotein(a) an independent risk factor for ischemic heart disease in men? The Quebec cardiovascular study. J Am Coll Cardiol 1998;31(3):519-25.
10. Dagenais GR, Robitaille NM, Lupien PJ, Christen A, Gingras S, Moorjani S, et al. First coronary heart disease event rates in relation to major risk factors: Quebec cardiovascular study. Can J Cardiol 1990;6(7):274-80.
11. Dagenais GR, Ahmed Z, Robitaille NM, Gingras S, Lupien PJ, Christen A, et al. Total and coronary heart disease mortality in relation to major risk factors - Quebec cardiovascular study. Can J Cardiol 1990;6(2):59-65.
12. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;16:285(19):2486-97.
13. Fruchart JC. Duriez P. Staels B. Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Curr Opinion Lipidol 1999;10(3):245-57.
14. Wooltorton E. Bayer pulls cerivastatin (Baycol) from market. CMAJ 2001; 165(5):632.
15. Herman RJ. Drug interactions and the statins. CMAJ 1999; 161(10):1281-6.
16. Holub BJ. Clinical nutrition: 4. Omega-3 fatty acids in cardiovascular care. CMAJ 2002;166(5):608-15.
17. Benlian P, De Gennes JL, Foubert L, Zhang H, Gagne SE, Hayden M. Premature atherosclerosis in patients with familial chylomicronemia caused by mutations in the lipoprotein lipase gene. N Engl J Med 1996;19:335(12):848-54.